$70.35
-2.3%Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
IRON • NASDAQ
| Disc Medicine, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-212.2M | -109.4M | -76.4M | -46.8M | -36M | -40.8M | |
281K | 156K | 100K | 89K | 32K | 322K | |
34.3M | 16.8M | 5.5M | 2.1M | 507K | 983K | |
-6.4M | -4.8M | 290K | 272K | 6.6M | 6.5M | |
(0.0) | (299K) | (112K) | (0.0) | (0.0) | (0.0) | |
3.5M | 3.2M | -3M | 2.1M | 1.3M | 337K | |
-180.4M | -93.9M | -73.5M | -42.3M | -27.5M | -32.7M | |
INVESTING ACTIVITIES | ||||||
-933K | -505K | -89K | -151K | -68K | -22K | |
-849.6M | -386.6M | (0.0) | (0.0) | (0.0) | (0.0) | |
456.2M | 94.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
-394.3M | -292.3M | -89K | -151K | -68K | -22K | |
FINANCING ACTIVITIES | ||||||
472.8M | 187.3M | 199.1M | 53.5M | 0.0 | 0.0 | |
0.0 | 29M | 0.0 | 0.0 | -4.6M | 14M | |
578K | 2M | 40.3M | 95.5M | 4.7M | 163K | |
473.4M | 218.3M | 239.4M | 149M | 89.9M | 34.2M | |
CASH FLOW SUMMARY | ||||||
-101.3M | -167.9M | 165.8M | 106.6M | 62.3M | 1.5M | |
192.7M | 360.6M | 194.8M | 88.2M | 25.9M | 3.3M | |
91.4M | 192.7M | 360.6M | 194.8M | 88.2M | 4.8M | |
-181.3M | -94.4M | -73.6M | -42.4M | -27.6M | -32.7M |
IRON - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 07, 2025 | 2025 |
Continue your IRON research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.